What this means
Inherited mitochondrial cardiomyopathies arise from pathogenic variants affecting oxidative phosphorylation, mitochondrial DNA maintenance, cardiolipin remodeling, protein import, cofactor metabolism, and mitochondrial dynamics or proteostasis. These disorders may be cardiac-predominant or part of multisystem disease.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- People
- Kind of research
- A summary of earlier studies
The science
- Original title
- Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework.
- Authors
- Lee CL, Chuang CK, Chang YH et al.
- Journal
- International journal of molecular sciences
- Published
- Sep 26, 2026
- Study type
- Review · in humans
- PMID
- 42794697 ↗
Abstract
Inherited mitochondrial cardiomyopathies arise from pathogenic variants affecting oxidative phosphorylation, mitochondrial DNA maintenance, cardiolipin remodeling, protein import, cofactor metabolism, and mitochondrial dynamics or proteostasis. These disorders may be cardiac-predominant or part of multisystem disease. Their overlapping cardiac phenotypes suggest convergence on interacting pathways of energetic stress, cristae disruption, calcium imbalance, and redox injury, but do not establish a universal requirement for defective mitophagy. Mitochondrial quality control encompasses protein surveillance, membrane remodeling, dynamics, biogenesis, and organelle disposal; mitophagy is one component. We critically examine the hypothesis that inadequate clearance of damaged mitochondria contributes to progression in a subset of genotypes and disease stages. Disease-specific studies provide support in selected Barth syndrome models, whereas findings in frataxin deficiency vary with model and assay. We distinguish mitochondrial delivery to lysosomes, dynamic turnover measurements, and changes in pathway markers, and identify indirect evidence from acquired heart disease and fatty acid oxidation deficiency. Therapeutic evidence is separated into cellular, animal, and human studies and approved indications. Elamipretide has accelerated approval for muscle-strength improvement in patients with Barth syndrome weighing at least 30 kg; cardiac disease modification remains unconfirmed. Gene replacement has reached early clinical testing, including adeno-associated virus-mediated frataxin gene delivery (AAV-FXN), whereas mitochondrial genome editing and selective mitophagy modulation remain investigational. We propose testable predictions addressing progression, selective rescue, and treatment timing, together with outcomes that would challenge the hypothesis. This framework supports genotype- and stage-specific investigation without assuming that enhanced mitophagy will benefit every mitochondrial cardiomyopathy.
Lee CL, Chuang CK, Chang YH et al. Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework. International journal of molecular sciences. 2026. doi:10.3390/ijms27188270. PMID: 42794697. https://pubmed.ncbi.nlm.nih.gov/42794697/
Related research
The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets.
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling.
A peptide eased signs of aging in heart cells damaged by a cancer drug
Researchers treated heart muscle cells in a dish with a cancer drug, then a peptide called SS-31. The peptide reduced several signs of aging, but not cell cycle arrest. This was done only in lab cells, so it does not show the peptide would help people.
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Peptide SS-31 eased radiation-caused aging signs in heart cells
Researchers exposed heart cells to radiation and gave some of them SS-31. SS-31 reduced several aging signs, but this was only tested in cells, not people.
Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society.
Two mitochondria-targeted drugs studied in aged female mice with fatty liver disease
Researchers gave two drugs to older mice with fatty liver disease caused by a rich diet. Both drugs improved liver markers in the mice, but this does not show they would help people.
See all research on Elamipretide (SS-31) →